BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33338858)

  • 1. Regorafenib in glioblastoma recurrence: A case report.
    Detti B; Scoccianti S; Lucidi S; Maragna V; Teriaca MA; Ganovelli M; Desideri I; Lorenzetti V; Scoccimarro E; Greto D; Livi L
    Cancer Treat Res Commun; 2021; 26():100263. PubMed ID: 33338858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Lombardi G; De Salvo GL; Brandes AA; Eoli M; Rudà R; Faedi M; Lolli I; Pace A; Daniele B; Pasqualetti F; Rizzato S; Bellu L; Pambuku A; Farina M; Magni G; Indraccolo S; Gardiman MP; Soffietti R; Zagonel V
    Lancet Oncol; 2019 Jan; 20(1):110-119. PubMed ID: 30522967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis.
    Indraccolo S; De Salvo GL; Verza M; Caccese M; Esposito G; Piga I; Del Bianco P; Pizzi M; Gardiman MP; Eoli M; Rudà R; Brandes AA; Ibrahim T; Rizzato S; Lolli I; Zagonel V; Lombardi G
    Clin Cancer Res; 2020 Sep; 26(17):4478-4484. PubMed ID: 32518098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma.
    Caccese M; Desideri I; Villani V; Simonelli M; Buglione M; Chiesa S; Franceschi E; Gaviani P; Stasi I; Caserta C; Brugnara S; Lolli I; Bennicelli E; Bini P; Cuccu AS; Scoccianti S; Padovan M; Gori S; Bonetti A; Giordano P; Pellerino A; Gregucci F; Riva N; Cinieri S; Internò V; Santoni M; Pernice G; Dealis C; Stievano L; Paiar F; Magni G; De Salvo GL; Zagonel V; Lombardi G
    ESMO Open; 2024 Apr; 9(4):102943. PubMed ID: 38492275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).
    Lombardi G; Del Bianco P; Brandes AA; Eoli M; Rudà R; Ibrahim T; Lolli I; Rizzato S; Daniele B; Pace A; Pasqualetti F; Caccesse M; Bergo E; Magni G; De Salvo GL; Zagonel V
    Eur J Cancer; 2021 Sep; 155():179-190. PubMed ID: 34388515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of glioblastoma stem cell markers OLIG2 and CCND2.
    Bouchart C; Trépant AL; Hein M; Van Gestel D; Demetter P
    Cancer Med; 2020 Feb; 9(3):1069-1078. PubMed ID: 31568682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: final report of a pilot study.
    Balducci M; Diletto B; Chiesa S; D'Agostino GR; Gambacorta MA; Ferro M; Colosimo C; Maira G; Anile C; Valentini V
    Strahlenther Onkol; 2014 Apr; 190(4):370-6. PubMed ID: 24429479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glioblastoma: Overview of Disease and Treatment.
    Davis ME
    Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S2-8. PubMed ID: 27668386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
    Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
    Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glioblastoma: patterns of recurrence and efficacy of salvage treatments.
    Oh J; Sahgal A; Sanghera P; Tsao MN; Davey P; Lam K; Symons S; Aviv R; Perry JR
    Can J Neurol Sci; 2011 Jul; 38(4):621-5. PubMed ID: 21672702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
    Hunn MK; Bauer E; Wood CE; Gasser O; Dzhelali M; Ancelet LR; Mester B; Sharples KJ; Findlay MP; Hamilton DA; Hermans IF
    J Neurooncol; 2015 Jan; 121(2):319-29. PubMed ID: 25366363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating recurrent glioblastoma: an update.
    Kamiya-Matsuoka C; Gilbert MR
    CNS Oncol; 2015; 4(2):91-104. PubMed ID: 25768333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dramatic response to regorafenib in early glioblastoma progression: case report and review of the literature.
    De Felice M; De Marinis P; Martin G; Bruscella S; De Bellis A; Poliero L; Turitto G
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5008-5013. PubMed ID: 35916797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spinal metastasis of glioblastoma multiforme before gliosarcomatous transformation: a case report.
    Hsu BH; Lee WH; Yang ST; Han CT; Tseng YY
    BMC Neurol; 2020 May; 20(1):178. PubMed ID: 32393192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of salvage treatment for recurrent glioblastoma.
    Kim HR; Kim KH; Kong DS; Seol HJ; Nam DH; Lim DH; Lee JI
    J Clin Neurosci; 2015 Mar; 22(3):468-73. PubMed ID: 25595963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
    Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
    Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of glioblastoma: State of the art and future directions.
    Tan AC; Ashley DM; López GY; Malinzak M; Friedman HS; Khasraw M
    CA Cancer J Clin; 2020 Jul; 70(4):299-312. PubMed ID: 32478924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
    Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
    J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
    Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
    Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.